Peptides DB
Research-centric peptide and protocol reference hub

IGF-1 DES (Des(1-3) IGF-1) record · updated 18h ago

Muscle & body compHealing & recoveryGrade A · human clinicalResearch use only
All 22 studiesJump to the evidenceCompare
What is IGF-1 DES (Des(1-3) IGF-1) used for?

IGF-1 DES (Des(1-3) IGF-1) is a truncated IGF-1 analog studied for localized muscle growth and tissue repair, with reduced IGFBP binding and higher local receptor activity.

How it works: IGF-1 receptor agonist

Primarily researched for · Muscle & body compRoute · Subcutaneous injection

Development stage

where IGF-1 DES (Des(1-3) IGF-1) sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 116 registered trials. It describes the research record, not a recommendation.

Identity
NameIGF-1 DES (Des(1-3) IGF-1)
Chain length—
Molecular weight—
Formula—
Structure type—
ClassMuscle
Research levelModerate Research
Discovered byCurated master list · 2026
Pharmacology
MechanismIGF-1 receptor agonist
RouteSubcutaneous injection
Half-life—
Time to peak—
Duration—
Extraction confidence0.80
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Sep 21, 2026. How this works →
Research stats
Total studies22
Human / animal / cellular13 / 2 / 4
Highest trial phasePhase 4
Years covered1995–2026
Latest study26d ago
Publication history
19952026
Research funding
1,325 NIH projects · $24.5M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

22 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Detection of LongR<sup>3</sup> -IGF-I, Des(1-3)-IGF-I, and R<sup>3</sup> -IGF-I using immunopurification and high resolution mass spectrometry for antidoping purposes.
FindingDes(1-3)-IGF-I and R<sup>3</sup>-IGF-I detectable until 24 h after 100 μg/kg IM injection in rats.
Animal2021Full text read0.80
N-terminal truncated insulin-like growth factor-I in human urine.
FindingTotal urinary IGF-I level was 216.0 +/- 41.1 ng/L (mean +/- SEM).
Human1995Full text read0.80
Interactions between growth hormone, insulin-like growth factor I, and basic fibroblast growth factor in melanocyte growth.
FindingNot reported in abstract.
In vitro1999Full text read0.70
The role of the acid-labile subunit in regulating insulin-like growth factor transport across human umbilical vein endothelial cell monolayers.
FindingNot reported in abstract.
In vitro2004Full text read0.70
Post-Endoscopic Retrograde Cholangiopancreatography Bleeding After Endoscopic Stone Removal in Dialysis Patients: A Multicenter Retrospective Study.
Finding8% of patients experienced bleeding.
Human2023Full text read0.80
Bethesda Endoscopic Retrograde Cholangiopancreatography Skill Assessment Tool (BESAT)-Based Simulator Training Using a Novel Dry Endoscopic Retrograde Cholangiopancreatography Model Improves Technical Proficiency and Self-Efficacy: A Prospective Study.
FindingEST success rate increased from 43.3% to 76.7% (p < 0.05).
Human2026Full text read0.80
Neutrophil serine proteases inhibit thermogenic capacity of visceral white adipose tissue.
TakeawayNot reported in abstract.
—2026Title only0.10
Risk Factors for Peritonitis Associated With Endoscopic Ultrasound-guided Hepaticogastrostomy.
FindingBile duct diameter ≤3 mm had an odds ratio of 4.0 for peritonitis, p=0.039.
Human2026Full text read0.80
Discontinuation of statins for primary prevention of atherosclerotic cardiovascular disease in adults aged 75 years or older (SAGA/SITE): a multicentre, open-label, pragmatic, non-inferiority randomised trial.
FindingThe absolute difference in all-cause mortality between groups was -0.68% (95% CI -3.95 to 2.60).
Human2026Full text read0.90
Efficacy and safety of filgotinib in patients with active radiographic and nonradiographic axial spondyloarthritis: results from OLINGUITO, a phase 3 trial consisting of 2 randomised, placebo-controlled, double-blind, parallel-group studies.
Finding39.5% ASAS40 response in r-axSpA filgotinib group vs 20.9% PBO, P=0.001, n=258.
Human2026Full text read0.90
Clinical Outcomes After Failed Endoscopic Detorsion for Sigmoid Volvulus: A Single-Center Retrospective Cohort Study.
FindingSuccessful detorsion achieved in 21 of 43 patients (48.8%).
Human2026Full text read0.80
Risk Stratification for Rebleeding in Obscure Gastrointestinal Bleeding After Comprehensive Gastrointestinal Evaluation.
FindingRebleeding rates were 5.6%, 17.5%, 27.3%, and 100% for scores 0, 1, 2, and 3, respectively.
Human2026Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching IGF-1 DES (Des(1-3) IGF-1) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much IGF-1 DES (Des(1-3) IGF-1) is discussed should be drawn from it.